Why is "Casirivimab/imdevimab" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-03-23 13:44:14
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Insights into the structural differences between homo- and heterodimers enriched from a cocktail of monoclonal antibodies against SARS-CoV-2 - nature.com
-
Casirivimab and Imdevimab in Combination Is Safe in Pediatric COVID-19 - Infectious Disease Advisor
-
In a $1B+ deal, Modex joins with Regeneron to develop antibodies - BioWorld MedTech
-
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial - The Lancet
-
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 - NEJM
-
Regeneron readies new COVID-19 monoclonal antibodies after the emergence of Omicron - drugdiscoverytrends.com
-
REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19 - Clinical Trials Arena
-
VisualAbstract: Casirivimab and imdevimab reduced mortality in seronegative patients with COVID-19 - 2 Minute Medicine
-
Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19 - medRxiv
-
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial - The Lancet
-
FDA Authorizes Regeneron’s Monoclonal Antibody Treatment for COVID-19 - respiratory-therapy.com
-
FDA Authorizes Use of COVID-19 Antibody Therapy for Postexposure Prophylaxis - Medical Professionals Reference
-
Treatment for those sick with COVID-19 have progressed, but vaccines still paramount - UCHealth
-
The WHO has advised against the use of two antibody therapies against COVID – here’s what that means - The Conversation
-
FDA Revokes EUAs of Four COVID-19 Monoclonal Antibodies - MedPage Today
-
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles - nature.com
-
VisualAbstract: Subcutaneous casirivimab and imdevimab reduced symptomatic COVID-19 infection among asymptomatic positive individuals - 2 Minute Medicine
-
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19 - NEJM
-
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19 - NEJM
-
Monoclonal antibody levels and protection from COVID-19 - nature.com
-
News - Reduced Efficacy of Ronapreve (Casirivimab/Imdevimab) against Omicron Variant - Paul-Ehrlich-Institut
-
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies - ASM Journals
-
Regen-COV Reduces Viral Load in Patients Hospitalized with COVID-19 - Infectious Disease Special Edition
-
Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy - nature.com
-
Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, Mayo Clinic study finds - Mayo Clinic News Network
-
Monoclonal Antibodies: A New Treatment for Long COVID? - medscape.com
-
COVID-19: EMA recommends authorisation of two monoclonal antibody medicines - European Medicines Agency
-
Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV - PMLiVE
-
FDA Authorizes REGEN-COV for Post-Exposure Prophylaxis for COVID-19 - Infectious Disease Special Edition
-
FDA halts use of REGEN-COV, Eli Lilly monoclonal antibodies - McKnight's Long-Term Care News
-
World Health Organization Releases Updated Guidelines on Treatment Strategies for COVID-19 - Renal and Urology News
-
Multiple Error Pathways Possible with Monoclonal Antibody Products for COVID-19 - ECRI
-
Warp Speed readies to distribute new drug cocktail for COVID-19 - army.mil
-
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies - The Lancet
-
Ronapreve: new COVID-19 treatment has just been authorised – here’s everything you need to know - The Conversation
-
Hamilton monoclonal antibody clinic sees 'incredible results' for high-risk COVID patients - CBC
-
FDA limits use of two COVID-19 monoclonal antibody therapies - American Hospital Association
-
REGEN-COV Joins COVID-19 Treatment List; WHO and MSF Call for Lower Prices and Increased Access - Health Policy Watch
-
FDA Expands Regeneron EUA for COVID-19 Antibody "Cocktail" - Genetic Engineering and Biotechnology News
-
Casirivimab and imdevimab reduce incidence of symptomatic COVID-19 - Hospital Pharmacy Europe
-
Another piece in the COVID-19 treatment puzzle - The Lancet
-
EMA receives application for marketing authorisation for Ronapreve (casirivimab / imdevimab) for treatment and prevention of COVID-19 - Agenzia Italiana del Farmaco
-
Warm autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis/macrophage activation syndrome occurring after COVID19 infection and administration of Casirivimab + Imdevimab (COVID19 monoclonal antibody) - onlinelibrary.wiley.com
-
Regeneron says antibody cocktail provides long-term protection from COVID-19 - Healio
-
Are Monoclonal Antibodies the Future of Long COVID Treatments? - Technology Networks
-
REGEN-COV works as COVID post-exposure prophylaxis, study says - CIDRAP
-
UK approves Regeneron’s COVID-19 antibody cocktail - PMLiVE
-
Regeneron puts kibosh on 4 antibody studies as Pfizer's Paxlovid dominates the COVID treatment scene - Fierce Pharma
-
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration - nature.com
-
A clear picture of the cost and efficacy of COVID-19 outpatient treatments - McGill University Health Centre
-
REGEN-COV cuts viral load within 7 days in COVID-19 patients - drugdiscoverytrends.com
-
WHO backs Regeneron COVID-19 drug cocktail - with equal access, price cut - UN News
-
Regeneron monoclonal antibody replacing bamlanivimab to keep COVID-19 patients out of the hospital | Louisville - Norton Healthcare
-
FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19 - PMLiVE
-
Drug Combo Greatly Reduced Severe COVID, Death in Outpatients - medscape.com
-
Monoclonal antibody therapies against SARS-CoV-2 - The Lancet
-
RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response - RECOVERY Trial
-
More Transmissible Delta Variant Dances Around COVID Vaccines - science.thewire.in
-
Feds approve Regeneron’s antibody therapy as COVID-19 preventive - McKnight's Long-Term Care News
-
Regeneron's COVID-19 antibody cocktail pads case for saving lives in hospitalized patients as FDA decision nears - Fierce Pharma
-
Regeneron’s Covid-19 antibodies help those who can’t make their own - Chemistry World
-
Regeneron, UPenn Gene Therapy Program Partner on COVID-19 Treatment via Nasal Spray - Inside Precision Medicine
-
COVID-19 treatment: Roche, Cipla launch antibody cocktail Casirivimab and Imdevimab in India, costs Rs... - Moneycontrol.com
-
MSF demands newest COVID-19 treatment recommended by WHO must be accessible to all - Express Pharma
-
Coronavirus antibody therapies explained - dw.com
-
A man who had COVID-19 for 411 days is finally cured - Scimex
-
Study finds some antibody therapies are not effective against new COVID-19 variants - European Pharmaceutical Review
-
Ascension Sacred Heart relaunches monoclonal antibody treatment for mild COVID-19 cases - Pensacola News Journal
-
Roche India gets CDSCO nod to COVID antibody cocktail of Casirivimab, Imdevimab - Medical Dialogues
-
Regeneron clinic in Fort Pierce under capacity in opening days as COVID cases spike - Treasure Coast News
-
Call to keep antibody cocktail drug available for Covid care in AP - Deccan Chronicle
-
Regeneron CEO Schleifer, chief scientist Yancopoulos bag massive $270M payday - Fierce Pharma
-
EMA recommends six medications for approval in February meeting - European Pharmaceutical Review
-
FDA authorizes REGEN-COV for post-exposure prophylaxis - EMS1
-
FDA grants EUA for Regeneron’s antibody cocktail to prevent Covid-19 - Pharmaceutical Technology
-
newsGP - What is the latest on COVID-19 treatments available in Australia? - Royal Australian College of General Practitioners (RACGP)
-
Regeneron, Roche COVID-19 antibody cocktail slashes hospitalizations and tackles variants in phase 3 - Fierce Pharma
-
Japan to OK experimental COVID-19 drug that Trump took - 朝日新聞
-
FDA bans Lilly, Regeneron antibody use in COVID-19 patients infected by omicron - Fierce Pharma
-
Swann welcomes Ronapreve for treatment of Covid-19 - health-ni.gov.uk
-
Which medicine works best for Covid-19 treatment? WHO answers - The Economic Times
-
Australia secures additional COVID-19 treatments - Australian Government Department of Health, Disability and Ageing
-
newsGP - Which medicines could be in short supply in 2022? - Royal Australian College of General Practitioners (RACGP)
-
TIL: How Effective Are The New COVID-19 Treatments? - Indiaspend
-
Roche’s Antibody Cocktail launched in India at Rs 59,750/dose - The Indian Express
-
Roche reports promising results from anti-COVID-19 cocktail - Times of Malta
-
Ronapreve: 'Most vulnerable' to get new Covid drug next week - BBC
-
Roche’s antibody Covid drug now available in India - Telangana Today
-
Roche reports promising results from anti-Covid cocktail - The Malaysian Reserve
-
Narayan Memorial Hospital Behala successfully conducts 'Antibody Cocktail Therapy' on two of its patients - ibgnews.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.